It remains controversial whether the EGFR pathway plays a role in the prognosis of non-small cell lung cancer (NSCLC) (Liu et al., 2017), while combined Retinoblastoma 1 (RB1) and Tumor Protein 53 (P53) mutations lead to poorer clinical outcomes in small cell lung cancer (SCLC) (Solta et al., 2024). This evidence concerns the gene EGFR and small cell lung carcinoma.